MicroRNA expression profile of MCF-7 human breast cancer cells and the effect of green tea polyphenon-60

Cancer Genomics and Proteomics

Volumn 7, Issue 5, 2010, Pages 261-278

  Fix, Lindsey N ^a   Shah, Maitri ^a   Efferth, Thomas ^b   Farwell, Mary A ^a   Zhang, Baohong ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

^b JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Breast cancer; Gene expression; Green tea; MCF 7; Micro RNA; Microarray; Polyphenon 60

Indexed keywords

ALPHA TROPOMYOSIN; GREEN TEA EXTRACT; MICRORNA; POLYPHENON 60; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; GENE CONTROL; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; RISK REDUCTION; TEA; TUMOR SUPPRESSOR GENE;

EID: 78149275673     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (135)

1. Catzavelos C, Bhattacharya N, Ung YC, Wilson JA, Roncari L, Sandhu C, Shaw P, Yeger H, Morava-Protzner I, Kapusta L, Franssen E, Pritchard KI and Slingerland JM: Decreased levels of the cell-cycle inhibitor p27Kip1 protein: prognostic implications in primary breast cancer. Nat Med 3: 227-230, 2007.
2. Teixeira C, Reed JC and Pratt MA: Estrogen promotes chemotherapeutic drug resistance by a mechanism involving Bcl- 2 proto-oncogene expression in human breast cancer cells. Cancer Res 55: 3902-3907, 1995.
3. Wang TT and Phang JM: Effects of estrogen on apoptotic pathways in human breast cancer cell line MCF-7. Cancer Res 55: 2487-2489, 1995.
4. Frasor J, Weaver A, et al: Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer. Cancer Res 69(23): 8918-25, 2009.
5. Eccles SA: The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 6(4): 393-406, 2001.
6. 2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools. Am J Clin Pathol 129(2): 263-273, 2008.
7. Lebeau A and Deimling D et al: Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 19(2): 354-363, 2001.
8. King MC and Marks JH et al: Breast and ovarian cancer risks due to inherited mutations in BRCAI and BRCA2. Science 302(5645): 643-646, 2003. (Pubitemid 37310920)
9. Rowinsky EK and Eisenhauer EA et al: Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 20(4 Suppl 3): 1-15, 1993.
10. Blenkiron C and Goldstein LD et al: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biology 8(10): 2007.
11. Zhang B and Pan X et al: microRNAs as oncogenes and tumor suppressors. Dev Biol 302(1): 1-12, 2007.
12. Frankel LB and Christoffersen NR et al: Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283(2): 1026-1033, 2008.
13. Si ML and Zhu S et al: miR-21-mediated tumor growth. Oncogene 26(19): 2799-2803, 2007.
14. Sun M and Estrov Z et al: Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther 7(3): 464-473, 2008. (Pubitemid 351482129)
15. Zhu SM and Si ML et al: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282(19): 14328-14336, 2007.
16. Bolstad BM and Irizarry RA et al: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19(2): 185-193, 2003.
17. Chen CF and Ridzon DA et al: Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33(20): e179, 2005.
18. Blower PE and Chung JH et al: MicroRNAs modulate the chemosensitivity of tumor cells. Molec Cancer Therapeutics 7(1): 1-9, 2008.
19. Marsit CJ and Eddy K et al: MicroRNA responses to cellular stress. Canc Res 66(22): 10843-10848, 2006.
20. Moffat ID, Boutros PC et al: MicroRNAs in adult rodent liver are refractory to dioxin treatment. Toxicological Sciences 99(2): 470-487, 2007.
21. Pogribny IP and Tryndyak VP et al: Induction of microRNAome deregulation in rat liver by long-term tamoxifen exposure. Mutat Res 619(1-2): 30-37, 2007.
22. Rossi L and Bonmassar E et al: Modification of miR gene expression pattern in human colon cancer cells following exposure to 5-fluorouracil in vitro. Pharmacol Res 56(3): 248-253, 2007.
23. Saito Y and Liang G et al: Specific activation of microRNA-127 with down-regulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9(6): 435-443, 2006.
24. Zhang BH and Pan XP: RDX induces aberrant expression of microRNAs in mouse brain and liver. Environmental Health Perspectives 117(2): 231-240, 2009.
25. Piriyapongsa J and Marino-Ramirez L et al: Origin and evolution of human microRNAs from transposable elements. Genetics 176(2): 1323-1337, 2007. (Pubitemid 46961124)
26. Wang WX and Rajeev BW et al: The expression of microRNA miR-107 decreases early in Alzheimer's disease and may accelerate disease progression through regulation of beta-site amyloid precursor protein-cleaving enzyme 1. J Neurosci 28(5): 1213-1223, 2008.
27. Volinia S and Calin GA et al: A microRNA expression signature of human solid tumors defines cancer gene targets. PNAS 103(7): 2257-2261, 2006.
28. Wilfred BR and Wang WX et al: Energizing miRNA research: A review of the role of miRNAs in lipid metabolism, with a prediction that miR-103/107 regulates human metabolic pathways. Mol Genetics Metab 91(3): 209-217, 2007.
29. Liu WH and Yeh SOH et al: MicroRNA-18a Prevents estrogen receptor-alpha expression, promoting proliferation of hepatocellular carcinoma cells. Gastroenterology 136(2): 683-693, 2009.
30. Wang Y and Weng TT et al: Identification of rat lung-specific microRNAs by microRNA microarray: valuable discoveries for the facilitation of lung research. BMC Genomics 8, 2007.
31. Yu F and Yao H et al: let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 131(6): 1109-23, 2007. (Pubitemid 350235025)
32. Guttilla IK and White BA: Coordinate Regulation of FOXO1 by miR-27a, miR-96, and miR-182 in Breast Cancer Cells. J Biol Chem 284(35): 23204-23216, 2009.
33. Liu T and Tang H et al: MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett 273(2): 233-42, 2009.
34. Xi YG and Shalgi R et al: Differentially regulated micro-RNAs and actively translated messenger RNA transcripts by tumor suppressor p53 in colon cancer. Clin Cancer Res 12(7): 2014-2024, 2006.
35. Lee YS and Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev 21(9): 1025-1030, 2007.
36. Johnson CD, Esquela-Kerscher A, et al: The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res 67(16): 7713-22, 2007. (Pubitemid 47281364)
37. Gottardo FLC, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM and Baffa R: Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25(5): 387-392, 2007. (Pubitemid 47362758)
38. Perkins DO, Jeffries CD, et al: microRNA expression in the prefrontal cortex of individuals with schizophrenia and schizoaffective disorder. Genome Biol 8(2): R27, 2007.
39. Bendoraite A, Knouf EC, et al: Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol 116(1): 117-25.
40. Meng F, Henson R, et al: Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130(7): 2113-29, 2006.
41. Saba R, Goodman CD, et al: A miRNA signature of prion induced neurodegeneration. PLoS One 3(11): e3652, 2008.
42. Sonkoly E: MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS ONE 2(7): e610, 2007.
43. Greither T, Grochola LF, et al: Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 126(1): 73-80.
44. Schetter AJ, Leung SY, et al: MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 299(4): 425-436, 2008.
45. Adamia S, AvetLoiseau H, et al: MicroRNA expression profile identifies distinct clinically relevant sub-groups in multiple myeloma: Novel Prognostic Markers and Potential Targets for Therapy, 2008.
46. Kim S, Choi M, et al: Identifying the target mRNAs of microRNAs in colorectal cancer. Comp Biol Chem 33(1): 94-99, 2009.
47. Pichiorri F, S. Suh S, et al: MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 105(35): 12885-12890, 2008.
48. Malzkorn B, Wolter M, et al: Identification and functional characterization of microRNAs involved in the malignant progression of gliomas. Brain Pathol, 2009.
49. Connolly E, Tchaikovskaya T, et al: Knockdown of miRNAs encoded by the polycistron, miR-17-92, causes a partial reversion of the malignant phenotype of HepG2 cells. Hepatology 46(4): 530A-531A, 2007.
50. Northcott PA, Fernandez-L A, et al: The miR-17/92 polycistron is up-regulated in sonic hedgehog-driven medulloblastomas and induced by N-myc in sonic hedgehog-treated cerebellar neural precursors. Cancer Res 69(8): 3249-3255, 2009.
51. Meng F, Henson R, et al: MicroRNA-21 regulation of survival signaling: A novel mechanism of chemoresistance in cholangiocarcincoma. Gastroenterology 130(4): A429-A429, 2006.
52. Lui WO, Pourmand N, et al: Patterns of known and novel small RNAs in human cervical cancer. Cancer Res 67(13): 6031-6043, 2007.
53. Papagiannakopoulos T, Shapiro A, et al: MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. Cancer Res 68(19): 8164-8172, 2008.
54. Cervigne NK, Reis PP, et al: Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. Hum Mol Genet 18(24): 4818-29, 2009.
55. Park JK, Lee EJ, et al: Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 38(7): E190-E199, 2009.
56. Nakachi K, Suemasu K, et al: Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 89(3): 254-261, 1998. (Pubitemid 28197289)
57. Farabegoli F, Barbi C, et al: (-)-Epigallocatechin-3-gallate downregulates estrogen receptor alpha function in MCF-7 breast carcinoma cells. Cancer Detect Prev 31(6): 499-504, 2007. (Pubitemid 350181735)
58. Asangani IA, Rasheed SA, et al: MicroRNA-21 (miR-21) post- transcriptionally down-regulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 27(15): 2128-36, 2008.
59. Chen Y, Liu W, et al: MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett 272(2): 197-205, 2008.
60. Lu Z, Liu M, et al: MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 27(31): 4373-4379, 2008.
61. Krichevsky AM and Gabriely G: miR-21: a small multi-faceted RNA. J Cell Mol Med 13(1): x-53, 2009.
62. Fujita S, Ito T, et al: miR-21 Gene expression triggered by AP- 1 is sustained through a double-negative feedback mechanism. J Mol Biol 378(3): 492-504, 2008.
63. Lin YC, Hsieh LC, et al: Human TRIM71 and its nematode homologue are targets of let-7 MicroRNA and its zebrafish orthologue is essential for development. Mol Biol Evol 24(11): 2525-2534, 2007.
64. Meng F, Henson R, et al: The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 282(11): 8256-64, 2007. (Pubitemid 47093612)
65. Beitzinger M, Peters L, et al: Identification of human microRNA targets from isolated argonaute protein complexes. RNA Biol 4(2): 76-84, 2007.
66. Wu LG, Fan JH, et al: MicroRNAs direct rapid deadenylation of mRNA. PNAS 103: 4034-4039, 2006.
67. Johnson SM, Grosshans H, et al: RAS is regulated by the let-7 microRNA family. Cell 120(5): 635-647, 2005.
68. Shell S, Park SM, et al: Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci USA 104(27): 11400-11405, 2007.
69. Tsang WP and. Kwok TT: Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3. Apoptosis 13(10): 1215-22, 2008.
70. Tokumaru S, Suzuki M, et al: let-7 regulates Dicer expression and constitutes a negative feedback loop. Carcinogenesis 29(11): 2073-2077, 2008.
71. Nie K, Gomez M, et al: MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am J Pathol 173(1): 242-252, 2008.
72. Muller DW and Bosserhoff AK: Integrin beta3 expression is regulated by let-7a miRNA in malignant melanoma. Exp Dermatol 18(3): 310-310, 2009.
73. Park SM, Gaur AB, et al: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 22(7): 894-907, 2008.
74. Koscianska E, Baev V, et al: Prediction and preliminary validation of oncogene regulation by miRNAs. BMC Mol Biol 8, 2007.
75. Peng Y, Laser J, et al: Anti proliferative effects by Let-7 repression of high-mobility group A2 in uterine leiomyoma. Mol Cancer Res 6(4): 663-673, 2008.
76. Luzi E, Marini F, et al: Osteogenic differentiation of human adipose tissue-derived stem cells is modulated by the miR-26a targeting of the SMAD1 transcription factor. J Bone Mineral Res 23(2): 287-295, 2008.
77. Wong CF and Tellam RL: MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis. J Biol Chem 283(15): 9836-9843, 2008.
78. Chow TF, Youssef YM, et al: Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. Clin Biochem, 2009.
79. Pallasch CP, Patz M, et al: miRNA deregulation by epigenetic silencing disrupts suppression of the oncogene PLAGl in chronic lymphocytic leukemia. Blood 114(15): 3255-3264, 2009.
80. Schultz J, Lorenz P, et al: MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 18(5): 549-57, 2008.
81. Zheng L, Lv GC, et al: Effect of miRNA-10b in regulating cellular steatosis level by targeting PPAR-alpha expression, a novel mechanism for the pathogenesis of NAFLD. J Gastroenterol Hepatol, 2009.
82. Takahashi Y, Forrest AR, et al: MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One 4(8): e6677, 2009.
83. Kozaki KI, Imoto I, et al: Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Research 68(7): 2094-2105, 2008.
84. Roldo C, Missiaglia E, et al: MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Onco 24(29): 4677-4684, 2006.
85. Sayed D, Hong C, et al: MicroRNAs play an essential role in the development of cardiac hypertrophy. Circulation Res 100(3): 416-424, 2007.
86. Guo Y, Chen Z, et al: Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 68(1): 26-33, 2008.
87. Huang XH, Wang Q, et al: Bead-based microarray analysis of microRNA expression in hepatocellular carcinoma: miR-338 is downregulated. Hepatol Res 39(8): 786-94, 2009.
88. Beveridge NJ, Gardiner E, et al: Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiatry, 2009.
89. Sampson VB, Rong NH, et al: MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells. Cancer Res 67(20): 9762-70, 2007.
90. Marton S, Garcia MR, et al: Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 22(2): 330-338, 2008.
91. Fang W, Lin C, et al: Detection of let-7a microRNA by real-time PCR in colorectal cancer: a single-centre experience from China. Journal of International Medical Res 35(5): 716-723, 2007.
92. Zhang HH, Wang XJ, et al: Detection of let-7a microRNA by real-time PCR in gastric carcinoma. World J Gastroenterol 13(20): 2883-8, 2007.
93. Long XB, Sun GB, et al: Let-7a microRNA functions as a potential tumor suppressor in human laryngeal cancer. Oncol Rep 22(5): 1189-95, 2009.
94. Catto JWF, Miah S, et al: Distinct MicroRNA Alterations Characterize High- and Low-Grade Bladder Cancer. Cancer Res 69(21): 8472-8481, 2009.
95. Lui WO, Pourmand N, et al: Patterns of known and novel small RNAs in human cervical cancer. Cancer Research 67(13): 6031-6043, 2007.
96. Friedland DR, Eernisse R, et al: Cholesteatoma Growth and Proliferation: Posttranscriptional Regulation by MicroRNA-21. Otol Neurotol, 2009.
97. Fulci V, Chiaretti S, et al: Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood 109(11): 4944-51, 2007.
98. Wang P, Zou F, et al: microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 69(20): 8157-65, 2009.
99. Pezzolesi MG, Platzer P, et al: Differential expression of PTEN-targeting microRNAs miR-19a and miR-21 in Cowden syndrome. Am J Hum Genet 82(5): 1141-9, 2008.
100. Lawrie CH, Soneji S, et al: MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer 121(5): 1156-1161, 2007.
101. Eisenberg I, Eran A, et al: Distinctive patterns of microRNA expression in primary muscular disorders. Proceedings of the National Academy of Sciences of the United States of America 104(43): 17016-17021, 2007.
102. Mathe EA, Nguyen GH, et al: MicroRNA Expression in Squamous Cell Carcinoma and Adenocarcinoma of the Esophagus: Associations with Survival. Clin Cancer Res 15(19): 6192-6200, 2009.
103. Zhang Z, Li Z, et al: miR-21 plays a pivotal role in gastric cancer pathogenesis and progression. Lab Invest 88(12): 1358-1366, 2008.
104. Silber J, Lim DA, et al: miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. BMC Med 6: 14, 2008.
105. Corsten MF, Miranda R, et al: MicroRNA-21 knockdown disrupts glioma growth In vivo and displays synergistic cytotoxicity with neural precursor cell-delivered S-TRAIL in human gliomas. Cancer Res 67(19): 8994-9000, 2007.
106. Thum T, Gross C, et al: MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 456(7224): 980-U83, 2008.
107. Wang B, Majumder S, et al: Role of MicroRNA-155 at Early Stages of Hepatocarcinogenesis Induced by Choline-Deficient and Amino Acid-Defined Diet in C57BL/6 Mice. Hepatology 50(4): 1152-1161, 2009.
108. Liu M, Wu HD, et al: Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Research 19(7): 828-837, 2009.
109. Seike M, Goto A, et al: MiR-21 is an EGFR-regulated antiapoptotic factor in lung cancer in never-smokers. Proceedings of the National Academy of Sciences of the United States of America 106(29): 12085-12090, 2009.
110. Markou A, Tsaroucha EG, et al: Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem 54(10): 1696-1704, 2008.
111. Li T, Li D, et al: MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commu 383(3): 280-285, 2009.
112. Li JS, Huang HZ, et al: MiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis Inhibitor. Clin Cancer Res 15(12): 3998-4008, 2009.
113. Wang T, Zhang X, et al: A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 46(4): 336-47, 2007.
114. Ji RR, Cheng YH, et al: MicroRNA expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circulation Res 100(11): 1579-1588, 2007.
115. Dong S, Cheng Y, et al: MicroRNA expression signature and the role of microRNA-21 in the early phase of acute myocardial infarction. J Biol Chem 284(43): 29514-25, 2009.
116. Garzon R, Pichiorri F, et al: MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 26(28): 4148-4157, 2007.
117. Kuhn DE, Nuovo GJ, et al: Human chromosome 21-derived miRNAs are overexpressed in down syndrome brains and hearts. Biochem Biophys Res Commun 370(3): 473-7, 2008.
118. Jiang JM, Lee EJ, et al: Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res 33(17): 5394-5403, 2005. (Pubitemid 41548806)
119. Leucci E, Cocco M, et al: MYC translocation-negative classical Burkitt lymphoma cases: an alternative pathogenetic mechanism involving miRNA deregulation. J Pathology 216(4): 440-450, 2008.
120. Ozen M, Creighton CJ, et al: Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 27(12): 1788-1793, 2008. (Pubitemid 351380263)
121. Wang GF, Mao WM, et al: Epidermal growth factor receptor-regulated miR-125a-5p-a metastatic inhibitor of lung cancer. Febs Journal 276(19): 5571-5578, 2009.
122. Bueno MJ, Perez de Castro I, et al: Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression. Cancer Cell 13(6): 496-506, 2008. (Pubitemid 351763902)
123. Furuta M, Kozaki KI, et al: miR-124 and miR-203 are epigenetically silenced tumor-suppressive microRNAs in hepatocellular carcinoma. Carcinogenesis, 2009.
124. Tryndyak VP, Beland FA, et al: E-cadherin transcriptional down-regulation by epigenetic and microRNA-200 family alterations is related to mesenchymal and drug-resistant phenotypes in human breast cancer cells. Int J Cancer, 2009.
125. Tryndyak VP, Ross SA, et al: Down-Regulation of the microRNAs miR-34a, miR-127, and miR-200b in Rat Liver During Hepatocarcinogenesis Induced by a Methyl-Deficient Diet. Molecular Carcinogenesis 48(6): 479-487, 2009.
126. Gibbons DL, Lin W, et al: Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes & Development 23(18): 2140-2151, 2009.
127. Hu XX, Macdonald DM, et al: A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecologic Oncology 114(3): 457-464, 2009.
128. Budhu A, Jia HL, et al: Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 47(3): 897-907, 2008. (Pubitemid 351449681)
129. Chin LJ, Ratner E, et al: A SNP in a let-7 microRNA complementary site in the KRAS 3′ untranslated region increases non-small cell lung cancer risk. Cancer Res 68(20): 8535-8540, 2008.
130. Ji JF, Shi J, et al: MicroRNA Expression, Survival, and Response to Interferon in Liver Cancer. N England J Medicine 361(15): 1437-1447, 2009.
131. Huang QH, Gumireddy K, et al: The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nature Cell Biology 10(2): 202-U83, 2008.
132. Xi Y, Formentini A, et al: Noncoding miRNAs as novel prognostic factor for 5-fluorouracil adjuvant therapy in colorectal cancer. J Clinic Oncolo 24(18): 173S-173S, 2006.
133. Huang YS, Dai Y, et al: Hepatology - Microarray analysis of microRNA expression in hepatocellular carcinoma and non-tumorous tissues without viral hepatitis. J Gastroentero Hepato 23(1): 87-94, 2008.
134. Mertens-Talcott SU, Chintharlapalli S, et al: The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G(2)-M checkpoint in MDA-MB- 231 breast cancer cells. Cancer Res 67(22): 11001-11011, 2007.
135. Ben-Ami O, Pencovich N, et al: A regulatory interplay between miR-27a and Runx1 during megakaryopoiesis. Proceedings of the National Academy of Sciences of the United States of America 106(1): 238-243, 2009.